Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8's Q3 Revenues Jump on Development Fees

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 Technology has reported that its third-quarter revenues jumped sharply from $19,873 to $240,272 year over year.

The firm's revenues came mostly from technology development fees, which totaled $214,500 for the quarter ended April 30. Novartis is evaluating Accelr8's BACcel system for identifying the type and quantity of bacterial pathogens in clinical specimens through a technology evaluation agreement that was extended in April to June 30, 2011, and has been paying Accelr8 fees for several months.

Accelr8 posted a net loss of $123,994, or $.01 per share, for the quarter compared to a net loss of $361,144, or $.03 per share, for the third quarter a year ago.

Its R&D expenses increased to $126,918 from $108,415, while its SG&A spending declined to $183,127 from $231,549.

Accelr8 finished the quarter with $372,261 in cash and cash equivalents.

Shares of Accelr8 were down 20 percent at $3.94 in mid-afternoon trade Monday on the American Stock Exchange.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.